JP has me blocked, (lol), so I am responding to th
Post# of 30067
Posted On: 12/13/2014 8:48:13 AM
JP has me blocked, (lol), so I am responding to the board regarding his list. It's no wonder people get amped up on 'expectations' and milestones when someone constantly re-posts lists that don't align with what was just communicated at the last investor conference and literally create a so-called countdown clock of messages each day. Very unrealistic. In regard to the so called 'list', here are my comments:
- Once again, it does not align with the recent investor presentation at LD Micro
- GC stated in the presentation that 'milestones' were Q4-Q1, so we don't really know if they will fall in 2014 or 2015. It depends on how they want them rolled out and really when the FDA decides to respond to the ODD app for RP
- company never stated 'JV Partnership'. They have a partner.
- Partner validation of APP and CLIA, I believe, are two different steps
- Eltoprazine first patient dosed is likely to be January timeframe as the IND has not been submitted, or at least it has not been communicated publicly - it may have been submitted
- MANF ear tox data was not mentioned in the recent presentation
- MANF RP is not even on the list
- MANF Wolframs was mentioned in the recent presentation suggesting an update on the 'collaboration'. We don't know if it is retinal eye data or beta cell diabetes data or something else.
- it's not 'Goods' Manufacturing Practices, it's 'Good'
So, JP keeps posting a daily list that is not accurate, could be misleading, and sets unrealistic expectations in some instances - not to mention, the countdown until the end of year is annoying. I suggest they get deleted until he comes up with a list that is actually accurate and reflects current communication by the company.
I am very confident we will get significant news this year but I also believe it will continue into 2015. It's not all going to happen in the next 2 weeks. January is a good month for biotech and investors should want this. AMBS has a strategy and I trust it will be effective. I believe once the share price hits .20, AMBS will seriously start to consider RS at that point. Anything above is gravy. I am fine with that. Let's get to the Nasdaq and get the recognition and institutional investors this company deserves.
- Once again, it does not align with the recent investor presentation at LD Micro
- GC stated in the presentation that 'milestones' were Q4-Q1, so we don't really know if they will fall in 2014 or 2015. It depends on how they want them rolled out and really when the FDA decides to respond to the ODD app for RP
- company never stated 'JV Partnership'. They have a partner.
- Partner validation of APP and CLIA, I believe, are two different steps
- Eltoprazine first patient dosed is likely to be January timeframe as the IND has not been submitted, or at least it has not been communicated publicly - it may have been submitted
- MANF ear tox data was not mentioned in the recent presentation
- MANF RP is not even on the list
- MANF Wolframs was mentioned in the recent presentation suggesting an update on the 'collaboration'. We don't know if it is retinal eye data or beta cell diabetes data or something else.
- it's not 'Goods' Manufacturing Practices, it's 'Good'
So, JP keeps posting a daily list that is not accurate, could be misleading, and sets unrealistic expectations in some instances - not to mention, the countdown until the end of year is annoying. I suggest they get deleted until he comes up with a list that is actually accurate and reflects current communication by the company.
I am very confident we will get significant news this year but I also believe it will continue into 2015. It's not all going to happen in the next 2 weeks. January is a good month for biotech and investors should want this. AMBS has a strategy and I trust it will be effective. I believe once the share price hits .20, AMBS will seriously start to consider RS at that point. Anything above is gravy. I am fine with that. Let's get to the Nasdaq and get the recognition and institutional investors this company deserves.
(0)
(0)